Aurora kinase inhibitors: progress towards the clinic

HIGHLIGHTS

• who: Spindle pole and collaborators from the Laboratory of Experimental Medicine, Palacky University, Dundee , JJ, UK have published the research: Aurora kinase inhibitors: Progress towards the clinic, in the Journal: (JOURNAL)
• what: In this study, the median IC50 was reported as 61 nM, ALL cell lines displaying the highest sensitivity and rhabdomyosarcoma cell lines were the least sensitive. The main reason for targeting AKs is based on the fact that they are upregulated in many cancer types.
• how: The anti-tumor activity of SNS-314 was tested in several solid tumor xenograft models . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.